Transcription factor switching drives subtype-specific pancreatic cancer

转录因子转换驱动亚型特异性胰腺癌

阅读:3
作者:Shalini V Rao,Lisa Young,Danya Cheeseman,Sean Flynn,Niklas Krebs,Dominique-Laurent Couturier,Stephanie Mack,Rebecca Brais,Jill Temple,Amy Smith,Evangelia Papachristou,Catarina Pelicano,Chandra Sekhar Reddy Chilamakuri,Krzysztof Herka,Hideo Baba,Luay Farah,Phyllis F Cheung,Jens Siveke,Stéphane Guerrier,Luca Insolia,Michael Gill,Emily Archer Goode,Steven Kupczak,Yi Cheng,Giacomo Borsari,Duncan Jodrell,Clive D'Santos,Alasdair Russell,Barbara T Grünwald,Eva Serrao,Igor Chernukhin,Jason S Carroll

Abstract

Emerging evidence suggests that lineage-specifying transcription factors control the progression of pancreatic ductal adenocarcinoma (PDAC). We have discovered a transcription factor switching mechanism involving the poorly characterized orphan nuclear receptor HNF4G and the putative pioneer factor FOXA1, which drives PDAC progression. Using our unbiased protein interactome discovery approach, we identified HNF4A and HNF4G as reproducible, FOXA1-associated proteins, in both preclinical models and Whipple surgical samples. In the primary tumor context, we consistently find that the dominant transcription factor is HNF4G, where it functions as the driver. A molecular switch occurs in advanced disease, whereby HNF4G expression or activity decreases, unmasking FOXA1's transcriptional potential. Derepressed FOXA1 drives late-stage disease by orchestrating metastasis-specific enhancer-promoter loops to regulate the expression of metastatic genes. Overall survival is influenced by HNF4G and FOXA1 activity in primary tumor growth and in metastasis, respectively. We suggest that the existence of stage-dependent transcription factor activity, triggered by molecular compartmentalization, mediates the progression of PDAC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。